Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma

Table 2

Relationship between treatment response and clinicopathological factors.

	Treatment response			Multivariates
	SD/PD	CR/PR		OR (95% CI)
Age
60	58 (56.9%)	44 (43.1%)	1.000
60	11 (57.9%)	8 (22.1%)
Gender
Male	67 (57.3%)	50 (42.7%)	1.000
Female	2 (50%)	2 (50%)
Grade
Well	41 (53.2%)	36 (46.8%)
Moderate	24 (60%)	16 (40%)	0.165
Poor	4 (100%)	0 (0%)
Stage
IVa	13 (37.1%)	22 (62.9%)	0.005	1
IVb	56 (65.1%)	30 (34.9%)		0.310 (0.128–0.752)	0.010
T stage
1/2	15 (53.6%)	13 (46.4%)	0.674
3/4	54 (58.1%)	39 (41.9%)
N stage
Negative	16 (40.0%)	24 (60.0%)	0.008	1
Positive	53 (65.4%)	28 (34.6%)		0.354 (0.151–0.834)	0.017
Chemotherapy
PF	51 (63%)	30 (37%)	0.147
TPF	18 (45%)	22 (55%)
Alcohol drinking
Never	17 (56.7%)	13 (43.3%)	0.964
Yes	52 (57.1%)	39 (42.9%)
Smoking
Never	11 (37.9%)	18 (62.1%)	0.017
Yes	58 (63.0%)	34 (37.0%)
Betel nuts
Never	16 (51.6%)	15 (48.4%)	0.480
Yes	53 (58.9%)	37 (41.1%)
OPN
Positive	8 (29.6%)	19 (70.4%)	0.002	1
Negative	61 (64.9%)	33 (35.1%)		0.320 (0.120–0.854)	0.023

CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; PF, cisplatin/fluorouracil; TPF, docetaxel/cisplatin/fluorouracil; OR, odds ratio; CI, confidence interval.
Indicates significantly difference ().